UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.

Also called NCT07163624

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 211 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07163624
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07163624. Randomized; double masking; primary purpose treatment. Start 2025-03-22 (actual); primary completion 2025-11-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study
Acronym
T2DM
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
UBT251 Injection 2.0 mg and UBT251 Injection Placebo
Intervention (Drug)
UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo
Intervention (Drug)
UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo
Intervention (Drug)
UBT251 Injection 6.0 mg and UBT251 Injection Placebo
Intervention (Drug)
Semaglutide Injection (Ozempic®)
Lead sponsor
The United Bio-Technology (Hengqin) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07163624
Content hash
97c13ef69e148ce0a30bb037f55d6471f9d495d30fcc5e3f27ecb2b23468a606